Latest New Zealand News

Plato Global Alpha Fund delivered a 26.7% net return for the year ended 30 June 2026, beating its global equity benchmark by 11.9 percentage points. Net assets climbed almost sixfold to $4.75 billion, driven by investment gains and substantial new applications, although the fund’s short positions and currency exposures remain material risks.

Michael Hill International has returned to profit growth and restored its dividend after a year of sharper execution, brand simplification and stronger cash generation. Record revenue and a 57% rise in comparable EBIT mark a meaningful recovery, although the reset remains unfinished.

Biome Australia Limited (ASX:BIO) delivered its second consecutive profitable year in FY26, with revenue rising 30% to $23.9 million and operating cash flow turning positive. But the headline $3.6 million profit includes a $2.4 million deferred tax benefit, leaving FY27 execution as the real test of the company’s growth plan.

Avira Resources is remobilising its RC rig to resume a 4,500-metre drilling program at Mt Cattlin, with first-pass holes planned at the historically high-grade Sirdar and Ellendale prospects. The next phase follows strong results from Maori Queen and Plantagenet, but the key test will be whether historical grades translate into repeatable mineralisation under Avira’s drilling.

Flynn Gold has returned to trading with a one-for-three renounceable rights issue priced at A$0.015, seeking up to approximately A$3 million for Tasmanian exploration. Only A$1.5 million is underwritten, leaving the final proceeds dependent on shareholder participation and shortfall demand.

EVT delivered growth across hotels, cinemas and Thredbo in FY2026 while outlining an approximately $500 million non-core property divestment programme. The group is also reviewing its structure as it redirects capital towards asset-light hotel expansion and considers potential special dividends.

The Colonial Motor Company (NZX:CMO) increased shareholder profit, lifted its annual dividend and sharply reduced borrowings and inventory in 2026. The New Zealand automotive group is entering a more difficult trading period, however, with price pressure, new-brand competition and a chair transition ahead.

Nyrada has secured AU$12.0 million from institutional and sophisticated investors, with a further AU$2.0 million shareholder purchase plan planned, giving the biotech funding to advance its Xolatryp clinical programs. The raise also carries substantial dilution and an unusually large proposed director subscription worth AU$5.125 million, subject to shareholder approval.

ReNerve has converted regulatory approvals into its first commercial NervAlign Nerve Cuff surgeries in Hong Kong and Malaysia, expanding activity to seven jurisdictions. The milestones arrive as FY26 sales climbed 88% to $510,357 and the company builds out its US distribution network.

Waterco Limited (ASX:WAT) delivered record FY26 EBIT of $23.8 million and lifted net profit after tax 59.6% to $15.4 million, despite only modest revenue growth. The stronger result supports a higher fully franked dividend, but the group is carrying more debt and inventory as it expands manufacturing capacity.

Orthocell has recorded the first commercial sales of its Remplir nerve repair product in Thailand, opening a new market estimated at US$84 million. The launch gives the company another distributor-led growth channel, although near-term sales are expected to remain modest.

Bannerman Energy has opened a non-underwritten share purchase plan targeting approximately A$10 million to support construction and working capital at its Etango uranium project in Namibia. The offer gives eligible Australian and New Zealand shareholders access to the same A$4.00 issue price as the company’s A$124 million institutional placement.